Last reviewed · How we verify
Meningococcal B
Meningococcal B vaccine stimulates the immune system to produce antibodies against serogroup B Neisseria meningitidis, preventing meningococcal disease.
Meningococcal B vaccine stimulates the immune system to produce antibodies against Neisseria meningitidis serogroup B, preventing meningococcal disease. Used for Prevention of meningococcal disease caused by Neisseria meningitidis serogroup B in infants, children, adolescents, and adults.
At a glance
| Generic name | Meningococcal B |
|---|---|
| Also known as | Bexsero |
| Sponsor | Canadian Immunization Research Network |
| Drug class | vaccine |
| Target | Neisseria meningitidis serogroup B surface antigens (recombinant proteins) |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains recombinant proteins from the meningococcal serogroup B capsule and outer membrane, which trigger both humoral and cellular immune responses. This generates protective antibodies and immune memory that prevent infection by serogroup B meningococci, the leading cause of bacterial meningitis and septicemia in developed countries.
Approved indications
- Prevention of meningococcal disease caused by Neisseria meningitidis serogroup B in infants, children, adolescents, and adults
Common side effects
- Injection site pain/erythema
- Fever
- Myalgia
- Fatigue
- Headache
- Nausea
Key clinical trials
- Safety and Efficacy Study of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) to Prevent Gonococcal Infection (PHASE2)
- Efficacy Trial on Meningococcal B Vaccine for Preventing Gonorrhea Infections (PHASE3)
- Phase IV Clinical Study of Immunogenicity of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) (PHASE4)
- Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae (PHASE2)
- Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants (PHASE3)
- A Phase I Clinical Trial to Assess the Safety and Immunogenicity of DX-104 (PHASE1)
- Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (PHASE3)
- Investigating Gender and Sex Differences in Immune Responses Through Vaccination of Transgender and Cisgender Persons (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Meningococcal B CI brief — competitive landscape report
- Meningococcal B updates RSS · CI watch RSS
- Canadian Immunization Research Network portfolio CI